RxDoctor Payments Data

Anand Swamy, DO

Family Medicine · Fountain Inn, SCNPI 1063049658

Payments from drug & device makers

$1,695in general payments, 2019–2025

Across 41 payments — averaging $41.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$300
  • Abbott$275
  • Dexcom, Inc.$273
  • Novartis$221
  • Amgen$121
  • Eisai Inc.$112
  • plus $393 from 8 others

What the payments were for

  • Food & beverage$1,695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,695 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$21,404
Medicare patients
80
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$41,322
JardianceEmpagliflozin22$27,672
MounjaroTirzepatide14$19,822
EliquisApixaban16$19,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,100
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,197
Albuterol Sulfate HfaAlbuterol Sulfate17$767
Atorvastatin Calcium85$585
Gabapentin39$481
Fluticasone Propionate20$457
Diclofenac Sodium17$455
Pravastatin Sodium25$441
Levothyroxine Sodium48$335
Metoprolol Succinate26$329
Valsartan19$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$81$41,32239 claims
Lilly USA, LLCMounjaro$96$19,82214 claims
PfizerEliquis$300$19,32516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Fountain Inn

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →